Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

Plain-language summary

This laboratory study analyzes biomarkers such as DNA methylation and gene expression in tissue samples from patients with high-risk Wilms tumor, a childhood kidney cancer. It enrolled patients with relapsed, anaplastic, or aggressive-type high-risk Wilms tumor. This study had no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Children's Oncology Group

Intervention

DNA methylation analysis, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis

Start date

5/1/2010

Countries

United States

Related genes

Locations

• Monrovia, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of high-risk Wilms tumor meeting ≥ 1 of the following criteria:

  * Relapsed disease
  * Anaplastic disease
  * Clear cell sarcomas of the kidney
  * Rhabdoid tumors
* Registered on NWTS-4, NWTS-5 (now COG-Q9401), or participation in AREN03B2 protocols with clinical follow-up \> 3 years
* Banked frozen tumor samples and paired normal DNA available with clinical data points, including the following:

  * Age, race, and gender
  * Stage and reason for stage
  * Tumor weight
  * Associated precursor lesions (rests)
  * Histologic subtype
  * Site and time of recurrence
  * Days of follow-up
  * Time and reasons for death (e.g., tumor, toxicity, infection, or other)